Clinical trials: Recurrent Tumor
Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma
Interstitial Photodynamic Therapy in Treating Patients With Recurrent Head and Neck Cancer
This phase II trial studies the effects of interstitial photodynamic therapy in patients with head and neck cancer that has come back.
- Conditions
- Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma, Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary
- Trial name
- NCT02068157
- Testing
- Laboratory Biomarker Analysis, Photodynamic Therapy, Porfimer Sodium
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Roswell Park Cancer Institute
Multiple Myeloma
SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma
A Phase 1/2, Open Label Study of SL-401 in Combination with Pomalidomide and Dexamethasone In Relapsed and Refractory Multiple Myeloma
- Trial name
- NCT02661022
- Testing
- SL-401 7 µg/kg/day, SL-401 9 µg/kg/day
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- Stemline Therapeutics, Inc.
Prostate Cancer, Prostatic Neoplasm
68Ga PSMA PET for Patients With Biochemical Recurrence of Prostate Cancer
This study investigates if a new prostate-specific membrane antigen (PSMA) drug makes prostate cancer easier to identify in positron-emission tomography (PET) imaging.
- Conditions
- Prostate Cancer, Prostatic Neoplasm, Prostatic Neoplasms, Castration-Resistant, Prostatic Cancer Recurrent
- Trial name
- NCT03389451
- Testing
- Ga-68 PSMA-HBED-CC PET
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Michael Graham PhD, MD
Advanced Malignant Mesothelioma, Epithelial Mesothelioma
PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery
This phase II trial is studying how well PXD101 works as second-line therapy in treating patients with malignant mesothelioma of the chest that cannot be removed by surgery.
- Conditions
- Advanced Malignant Mesothelioma, Epithelial Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatous Mesothelioma
- Trial name
- NCT00365053
- Testing
- belinostat, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- National Cancer Institute (NCI)
Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma
Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas
The purpose of this study is to evaluate how safe and effective the combination of two different drugs (brentuximab vedotin and rituximab) is in patients with certain types of lymphoma.
- Conditions
- Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma
- Trial name
- NCT01805037
- Testing
- brentuximab vedotin, rituximab, laboratory biomarker analysis
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Northwestern University
Clear Cell Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
This randomized phase III trial studies carboplatin, paclitaxel and gemcitabine hydrochloride when given together with or without bevacizumab after surgery to see how well it works in treating patients with ovarian, epithelial…
- Conditions
- Clear Cell Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma
- Trial name
- NCT00565851
- Testing
- Bevacizumab, Carboplatin, Docetaxel
- Where
- 709 sites in United States, Japan and 1 more
- Volunteers
- 1,052 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment
The purpose of the study (Part 1 and Part 2) is to evaluate the safety of a step-up dosing approach (starting with low doses followed by higher doses) of the study medicine (elranatamab) in participants with multiple myeloma that…
- Trial name
- MagnetisMM-9 (NCT05014412)
- Testing
- Elranatamab
- Where
- 50 sites in United States, Japan and 2 more
- Volunteers
- 86 people
- Sponsor
- Pfizer
Leptomeningeal Neoplasm, Metastatic Lung Non-Small Cell Carcinoma
Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer
This phase I/Ib trial studies the side effects and best dose of CB-839 HCl when given together with sapanisertib in treating patients with non-small cell lung cancer that has spread to other places in the body (advanced).
- Conditions
- Leptomeningeal Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Recurrent Lung Non-Small Cell Carcinoma
- Trial name
- NCT04250545
- Testing
- Sapanisertib, Telaglenastat Hydrochloride
- Where
- 7 sites in United States
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Loss of Chromosome 17p, Recurrent Chronic Lymphocytic Leukemia
Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation
This phase II trial studies how well nivolumab and ibrutinib work when given together in treating patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, or Richter transformation that has come back after a period…
- Conditions
- Loss of Chromosome 17p, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia
- Trial name
- NCT02420912
- Testing
- Ibrutinib, Laboratory Biomarker Analysis, Nivolumab
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- M.D. Anderson Cancer Center
Recurrent Melanoma, Stage IIIA Cutaneous Melanoma AJCC v7
Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
This randomized phase II trial studies how well ipilimumab with or without high-dose recombinant interferon alpha-2b works in treating patients with stage III-IV melanoma that cannot be removed by surgery.
- Conditions
- Recurrent Melanoma, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7
- Trial name
- NCT01708941
- Testing
- Ipilimumab, Laboratory Biomarker Analysis, Recombinant Interferon Alfa-2b
- Where
- 276 sites in United States
- Volunteers
- 88 people
- Sponsor
- National Cancer Institute (NCI)
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Vorinostat, Fluorouracil, and Leucovorin Calcium in Treating Patients With Metastatic Colorectal Cancer That Has Not Responded to Previous Treatment
RATIONALE: Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as fluorouracil and leucovorin calcium, work in different ways to stop the growth…
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer
- Trial name
- NCT00942266
- Testing
- fluorouracil, leucovorin calcium, vorinostat
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Roswell Park Cancer Institute
Chronic Lymphocytic Leukemia (CLL)
A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
The overall purpose of the study was to determine if MEDI-551, when used in combination with salvage chemotherapy (bendamustine) in participants with relapsed or refractory CLL who are not eligible for Autologous Stem Cell…
- Trial name
- NCT01466153
- Testing
- Rituximab, Bendamustine, MEDI-551
- Where
- 54 sites in United States, Belgium and 6 more
- Volunteers
- 183 people
- Sponsor
- MedImmune LLC
Multiple Myeloma
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
This is a Phase 2, open-label, multicenter study examining the safety, pharmacokinetics and pharmacodynamics, and best overall response to escalating doses of the proteasome inhibitor NPI-0052 (also known as marizomib) in…
- Trial name
- NCT00461045
- Testing
- MRZ 0.5 mg/m^2
- Where
- 6 sites in United States
- Volunteers
- 15 people
- Sponsor
- Celgene
Squamous Cell Cancer
Study of Sorafenib/Cetuximab in Head and Neck Cancer
In this Phase I B/II trial, we seek to determine the safety and efficacy of sorafenib with standard dose cetuximab in the treatment of patients with Recurrent and /or Metastatic Squamous Cell Carcinoma of the Head and Neck…
- Trial name
- NCT00815295
- Testing
- Sorafenib, Cetuximab
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Duke University
Recurrent Glioblastoma or Other Glioma Subtypes
A Phase 2 Study of BGJ398 in Patients With Recurrent GBM
This is an open-label non-randomized, multicenter, phase II study of BGJ398 administered to adult patients with histologically confirmed GBM and/or other glioma subtypes with FGFR1-TACC1, FGFR3-TACC3 fusion and/or activating…
- Trial name
- NCT01975701
- Testing
- BGJ398
- Where
- 17 sites in United States, Australia and 4 more
- Volunteers
- 26 people
- Sponsor
- Novartis Pharmaceuticals
Leukaemia, Lymphocytic, Chronic
Ofatumumab Added to Fludarabine-Cyclophosphamide vs Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic Leukemia
The purpose of this study was to evaluate the safety and efficacy of ofatumumab added to fludarabine-cyclophosphamide in patients with relapsed Chronic Lymphocytic Leukemia (CLL).
- Trial name
- NCT00824265
- Testing
- OFC Infusion, FC infusion
- Where
- 135 sites in United States, Brazil and 16 more
- Volunteers
- 365 people
- Sponsor
- Novartis Pharmaceuticals
Refractory Ovarian Cancer With Recurrent Symptomatic Malignant Ascites
Phase 1/2a Two-Arm Dose-Escalation Study of BAX69 in Subjects With Malignant Ascites of Ovarian Cancer
The purpose of this study is to evaluate the safety and tolerability of BAX69 monotherapy given either as intraperitoneal (IP) infusion (Single-Route Arm); or as IP infusion after intravenous (IV) infusion (IV+IP) (Double-Route…
- Trial name
- NCT02540356
- Testing
- BAX69 Single-Route Arm, BAX69 Double-Route Arm
- Where
- 6 sites in United States
- Volunteers
- 2 people
- Sponsor
- Baxalta now part of Shire
Endometrial Carcinoma
Trisenox® in Women With Metastatic Endometrial Cancer
The primary purpose of this study is to see whether women who have already received chemotherapy for their endometrial cancer, or who have disease that has spread outside of the uterus, will respond to the drug arsenic trioxide…
- Trial name
- NRR (NCT01184053)
- Testing
- Arsenic trioxide
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Malignant Glioma
Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas
The purpose of this study is to see if the addition of the investigation drug called pembrolizumab (Keytruda®) to radiation therapy and bevacizumab (Avastin®) is safe and can help with controlling the growth of tumors, in…
- Trial name
- NCT02313272
- Testing
- Hypofractionated Stereotactic Irradiation (HFSRT), Pembrolizumab, Bevacizumab
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Hodgkins Lymphoma
Avelumab In Patients With Previously Treated Advanced Stage Classical Hodgkin's Lymphoma (JAVELIN HODGKINS)
This is a Phase 1b, open-label, multi-center study comprising a lead-in phase and an expansion phase. The lead-in phase is a multiple-dose, randomized, parallel-arm, pharmacokinetic and pharmacodynamic study of avelumab as a…
- Trial name
- NCT02603419
- Testing
- Avelumab
- Where
- 13 sites in United States, Italy and 1 more
- Volunteers
- 34 people
- Sponsor
- Pfizer